<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996788</url>
  </required_header>
  <id_info>
    <org_study_id>037-IOB-0701</org_study_id>
    <nct_id>NCT00996788</nct_id>
  </id_info>
  <brief_title>Anti Free Radical &amp; Anti Inflammatory Effect &amp; Safety of Rebamipide in Chronic Gastritis</brief_title>
  <official_title>Anti Free Radical &amp; Anti Inflammatory Effect &amp; Safety of Rebamipide in Chronic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Otsuka Indonesia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Otsuka Indonesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the anti free radical &amp; inflammatory effect and safety of Rebamipide in patients
      suffering of dyspepsia due to chronic gastritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of Rebamipide 100 mg t.i.d. in reducing gastric mucosal damage due to free radical and inflammation</measure>
    <time_frame>2 times (at day-0 and day-28)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To confirm the improvement of dyspepsia syndrome</measure>
    <time_frame>3 times (at day-0, day-7 and day-28)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Chronic Gastritis</condition>
  <arm_group>
    <arm_group_label>Rebamipide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rebamipide 100 mg tid for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide</intervention_name>
    <description>Rebamipide 100 mg tid for 28 days</description>
    <arm_group_label>Rebamipide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who

          1. are 18 - 80 years old

          2. have symptoms of dyspepsia that need endoscopic examination

          3. are suffering from chronic moderate to severe gastritis which is confirmed
             endoscopically

          4. are able to give informed concern

        Exclusion Criteria:

        Patients who

          1. are treated with drugs that induce gastritis/ulcer, such as: NSAID

          2. are chronic alcoholism,

          3. are drug abuser

          4. are contraindicated for endoscopy examination

          5. has erosive or ulcerative esophagitis

          6. has peptic ulcer that has been confirmed by endoscopy

          7. has pyloric stenosis

          8. has active gastrointestinal bleeding

          9. has major absorption disorder

         10. has history of gastric surgery

         11. with renal disorder (creatinine &gt; 2 mg/dL)

         12. with liver disease ( SGOT, SGPT, bilirubin)

         13. have hematologic disorder ( confirmed with hemoglobin, erythrocytes,
             leucocytes,differential blood count)

         14. are suffering from congestive gastropathy due cirrhosis

         15. are suffering from congestive heart disease

         16. are pregnant or giving breast feeding

         17. are hypersensitive to Rebamipide

         18. are treated with gastroprotective drugs such as : teprenone, sucralfate.

         19. are treated with acid suppressing medicine (H2A, PPI)

         20. are treated with antibiotics, mesalazine (Salofalk)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aziz Rani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology Department of Internal Medicine - Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Gastroenterology Department of Internal Medicine - Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients suffering of dyspepsia due to chronic gastritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

